ALA ( DrugBank: - )
2 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 180 | ATR-X syndrome | 1 |
| 286 | Hereditary sideroblastic anemia | 2 |
180. ATR-X syndrome
Clinical trial : 1 / Drugs : 3 - (DrugBank : 2) / Drug target gene : 0 - Drug target pathway : 0
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-jRCT2051220062 | 14/07/2022 | 14/07/2022 | Physician-initiated clinical trial in patients with 5-aminolevulinic acid-induced ATR-X syndrome. | Exploratory study to investigate the safety and efficacy of NPJ005 in patients with ATR-X syndrome. - IACT21003 | ATR-X syndrome infant, intellectual disability, epigenetics, guanine quadruplex;D008607 | Containing 5-aminolevulinic acid (5-ALA) hydrochloride and sodium ferrous citrate (SFC) Tablets (25 mg 5-ALA hydrochloride/39.2 mg SFC per tablet, NPJ005) for 24 weeks | Wada Takahito | NULL | Recruiting | >= 2age old | Not applicable | Male | 5 | Phase 2 | Japan |
286. Hereditary sideroblastic anemia
Clinical trials : 7 / Drugs : 20 - (DrugBank : 10) / Drug target genes : 8 - Drug target pathways : 43
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-UMIN000023490 | 2016/08/20 | 05/08/2016 | The Safety and Efficacy of 5-Aminolevulinic Acid (ALA) Therapy for Sideroblastic Anemia | The Safety and Efficacy of 5-Aminolevulinic Acid (ALA) Therapy for Sideroblastic Anemia - The Safety and Efficacy of 5-Aminolevulinic Acid (ALA) Therapy for Sideroblastic Anemia | Sideroblastic anemia (congenital and acquired) | Food supplement containing 150 mg of ALA phosphate was given per day for 24 weeks. For the evaluation of efficacy and safety, medical examinations as well as urine and blood tests will be performed prior to administration of ALA, then at 2 and 4 weeks, and thereafter every month (up to 12 months). | Department of Hematolgy and Rheumatology, Tohoku University Graduate School of Medicine | NULL | Complete: follow-up complete | 20years-old | 80years-old | Male and Female | 5 | Not applicable | Japan |
| 2 | JPRN-UMIN000021407 | 2016/03/15 | 15/03/2016 | A study of efficacy and safety of 5-aminolevulinic acid phosphate in patients with sideroblastic anemia | A study of efficacy and safety of 5-aminolevulinic acid phosphate in patients with sideroblastic anemia - Efficacy and safety of 5-ALA phosphate in patients with sideroblastic anemia | sideroblastic anemia | Orally intake a 150 mg 5-aminolevulinic acid phosphate capsule once a day for up to 24 weeks. | Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University | SBI Pharmaceuticals Co., Ltd | Complete: follow-up continuing | 20years-old | 80years-old | Male and Female | 5 | Not applicable | Japan |